Roivant Sciences
NasdaqGS:ROIV Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
WA
Consensus Narrative from 7 Analysts
Late-stage Trials For Brepocitinib And Batoclimab Will Unlock Potential, But Execution Risks Remain
Key Takeaways Successful clinical trials and strategic deals may improve revenue and net margins by focusing on high-value areas. Potential in-licensing and late-stage pipeline approvals could significantly enhance earnings and portfolio sales impact.
View narrativeUS$16.14
FV
34.0% undervalued intrinsic discount59.17%
Revenue growth p.a.
1users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
about 1 month ago author updated this narrative